Madrigal Pharmaceuticals (MDGL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Shareholders will vote on the re-election of three Class I directors: Julian Baker, Daniel Brennan, and James Daly.
An advisory vote will be held to approve executive compensation.
Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 is on the agenda.
Approval of the 2026 Stock Plan and the 2026 Employee Stock Purchase Plan will be considered.
Other business matters may be addressed as appropriate during the meeting.
Board of directors and corporate governance
The board recommends voting in favor of all proposals presented at the annual meeting.
The meeting will be held virtually, allowing shareholders to participate online.
Executive compensation and say-on-pay
An advisory vote on executive compensation is included in the agenda, allowing shareholders to express their views.
Latest events from Madrigal Pharmaceuticals
- Q2 2026 net sales up 71% to $364.3M, with over 49,000 patients and robust pipeline progress.MDGL
Q2 20261 Aug 2026 - Q2 launch drove $14.6M sales, >2,000 patients, >50% coverage, and EU expansion plans.MDGL
Q2 20249 Jul 2026 - Rapid sales growth, pipeline innovation, and combination strategies drive MASH market leadership.MDGL
44th Annual J.P. Morgan Healthcare Conference9 Jul 2026 - Rezdiffra net sales neared $1B in 2025, fueling growth, pipeline expansion, and global rollout.MDGL
Q4 20258 Jul 2026 - Q1 net sales jumped 127% to $311M, with strong patient growth and expanding pipeline.MDGL
Q1 20268 Jul 2026 - $180.1M in 2024 sales, strong launch, and major guideline inclusion drive future growth.MDGL
Q4 20248 Jul 2026 - Strong U.S. growth, pipeline expansion, and key trial readouts expected by 2027.MDGL
TD Cowen 46th Annual Health Care Conference8 Jul 2026 - Q3 2024 net sales hit $62.2M with rapid Rezdiffra uptake and >80% coverage achieved early.MDGL
Q3 20248 Jul 2026 - Rezdiffra’s blockbuster launch and expanding pipeline position the company for sustained MASH market leadership.MDGL
Goldman Sachs 47th Annual Global Healthcare Conference 202610 Jun 2026 - Record sales, pipeline expansion, and strong governance drive long-term MASH leadership.MDGL
Proxy filing28 Apr 2026